With 69.7 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.14 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $51.19 whereas the lowest price it dropped to was $37.12. The 52-week range on QURE shows that it touched its highest point at $19.18 and its lowest point at $4.45 during that stretch. It currently has a 1-year price target of $64.42. Beta for the stock currently stands at 0.06.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of QURE was up-trending over the past week, with a rise of 235.45%, but this was up by 205.47% over a month. Three-month performance surged to 231.47% while six-month performance rose 230.78%. The stock gained 168.97% in the past year, while it has gained 786.19% so far this year. A look at the trailing 12-month EPS for QURE yields -3.92 with Next year EPS estimates of -3.14. For the next quarter, that number is -0.92. This implies an EPS growth rate of 33.65% for this year and 3.83% for next year. EPS is expected to grow by 44.31% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -9.66%.
Float and Shares Shorts:
At present, 54.87 million QURE shares are outstanding with a float of 49.01 million shares on hand for trading. On 2025-08-29, short shares totaled 9.06 million, which was 1651.0001 higher than short shares on 1753920000. In addition to Mr. Christian Klemt as the firm’s CFO, Principal Financial Officer & GM of Amsterdam Site, Dr. Jeannette Potts J.D., Ph.D. serves as its Chief Legal & Compliance Officer and Corporate Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, QURE reported revenue of $5262000.0 and operating income of -$42885000.0. The EBITDA in the recently reported quarter was -$36711000.0 and diluted EPS was -$0.69.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for QURE since 7 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With QURE analysts setting a high price target of 94.65389 and a low target of 13.250675, the average target price over the next 12 months is 54.832954. Based on these targets, QURE could surge 99.27% to reach the target high and fall by -72.1% to reach the target low. Reaching the average price target will result in a growth of 15.44% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.60167 being high and -$4.81146 being low. For QURE, this leads to a yearly average estimate of -$4.08212. The surprise factor in the prior quarter was -$0.93. Based on analyst estimates, the high estimate for the next quarter is $0.44 and the low estimate is -$1.28. The average estimate for the next quarter is thus -$0.62.
